Inovalon Holdings, Inc. Announces Date of Its 2017 Annual Meeting of Stockholders
Mar 14, 2017 11:55 am UTC| Business
BOWIE, Md., March 14, 2017 -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based models across the...
EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017
Mar 14, 2017 11:31 am UTC| Business
EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017 LYON, France, March 14, 2017 - EDAP TMS SA (NASDAQ: EDAP), the global leader in therapeutic ultrasound, today announced that it will...
BioNovelus Welcomes Internationally Respected Businessman and Innovator to Board of Directors
Mar 14, 2017 11:30 am UTC| Business
Phoenix, March 14, 2017 -- / BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce the appointment of internationally recognized business and financial consultant Anthony J. Parkinson to its board of directors....
Mar 14, 2017 11:30 am UTC| Business
Multicenter randomized study serves as unequivocal evidence of EXPAREL as an opioid minimizing agent in a complex and painful surgical procedure Protocol’s best practice infiltration technique for the use of EXPAREL will...
Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results
Mar 14, 2017 11:30 am UTC| Business
ALPHARETTA, Ga., March 14, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial...
Mar 14, 2017 11:30 am UTC| Business
Cyprium, NICHD establish CRADA to advance clinical development of Phase 3 candidate CUTX-101 (Copper Histidinate injection) inMenkes disease, a rare and fatal pediatric disease Cyprium licenses preclinical AAV-ATP7A gene...
Albireo Reports 2016 Financial Results
Mar 14, 2017 11:30 am UTC| Business
Promising Phase 2 data for A4250 in pediatric cholestatic liver disease Initiation of A4250 Phase 3 trial planned for 2H 2017 JNDA filing for elobixibat by licensee EA Pharma Consummation of business combination to...